Shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) currently hold a consensus rating of “Moderate Buy,” according to six analysts monitoring the stock. This consensus follows a series of evaluations that include one sell rating, four buy ratings, and one strong buy rating. The average target price among analysts who have assessed Artiva over the past year stands at $19.00.
Several analysts have recently issued reports regarding Artiva Biotherapeutics. On October 17, 2024, Wedbush raised its price target from $18.00 to $23.00, assigning the stock an “outperform” rating. In the same report, Needham & Company LLC reaffirmed a “buy” rating with a target price of $18.00.
In contrast, Weiss Ratings maintained a “sell (d-)” rating on the stock as of January 27, 2024. Additionally, HC Wainwright increased its price target from $12.00 to $15.00 with a “buy” rating on November 12, 2024. Furthermore, Jefferies Financial Group upgraded its rating to “strong buy” on November 18, 2024.
Recent Performance and Earnings Results
Artiva Biotherapeutics reported its latest earnings on November 12, 2024, revealing a loss of ($0.88) earnings per share. This result exceeded analysts’ expectations, which had estimated a loss of ($0.92) per share. Looking ahead, research analysts predict that the company will report an earnings per share of -4.95 for the current fiscal year.
Institutional Investor Activity
Recent institutional trading activity has significantly impacted Artiva Biotherapeutics. Citadel Advisors LLC increased its holdings in the company by an impressive 419.3% during the third quarter, now owning 798,397 shares valued at approximately $2.29 million after acquiring an additional 644,658 shares.
In addition, BNP Paribas Financial Markets boosted its stake by an astonishing 14,463.5%, acquiring 118,547 shares valued at around $340,000 after purchasing an additional 117,733 shares during the same period. Other notable investors include Marshall Wace LLP, which purchased a new stake valued at $79,000, and Jane Street Group LLC, which acquired shares worth $67,000.
About Artiva Biotherapeutics
Artiva Biotherapeutics is a clinical-stage biotechnology company specializing in the development of allogeneic “off-the-shelf” cell therapies for cancer. By leveraging engineered natural killer (NK) cells that express chimeric antigen receptors (CARs), the company aims to deliver effective anti-tumor activity while minimizing the safety and supply challenges associated with traditional patient-derived therapies. Artiva’s pipeline features several lead product candidates targeting both hematologic malignancies and solid tumors.
As the company continues to navigate the evolving biotechnology landscape, investor attention remains focused on its future developments and strategic partnerships.
